Researchers from the SWOG Cancer Research Network used methylation patterns in cell-free DNA extracted from blood samples to predict which patients with muscle-invasive bladder cancer were likely to benefit from chemotherapy before their surgery.
A research team led by UCLA Health Jonsson Comprehensive Cancer Center investigators has shown that combining pembrolizumab, an immunotherapy drug, with standard chemotherapy can improve treatment outcomes for patients with small cell bladder cancer and small cell/neuroendocrine prostate cancer.
